Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : CNBC -- critique. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (10857)	6/13/2002 12:27:05 PM
From: scaram(o)uche	Respond to of 17683

Bill Griffeth: You are correct. There was tons of enthusiasm re. potential cancer cures in the late 90s. There still is. Drug development takes time. The generation of "new target" drugs is just hitting the clinic. Gleevec is a peek, as Novartis ran early and hard. The new targets generated most of the enthusiasm of the late 90s. The EGF receptor was wound up in that, point taken. However, one can rest assured that exciting successes -- against a variety of cancers -- are virtually assured in the next 15-20 years. I have significant background and interest in cancer biology and immunology. I have been one of the most vociferous of critics of most industry-oncology programs. There are good companies, there are bad companies, and there are sloppy companies. IMO, Imclone was sloppy with intent. Let's move on, instead of damning sincere efforts with broad strokes. We're talking medicines and cancer, and the new age of target-driven discovery is only about five years running. Thank you. Rick